LIFECORE BIOMEDICAL, INC. Finance Lease, Liability, Noncurrent
LIFECORE BIOMEDICAL, INC. (LFCR) had Finance Lease, Liability, Noncurrent of $5.59 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:FinanceLeaseLiabilityNoncurrent · last filed 2026-08-05
- 2026-06-30: Finance Lease, Liability, Noncurrent $5.59M.
- 2026-03-31: Finance Lease, Liability, Noncurrent $5.64M.
- 2025-12-31: Finance Lease, Liability, Noncurrent $5.69M.
- 2025-09-30: Finance Lease, Liability, Noncurrent $5.74M.
| Period end | Finance Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $5.59M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $5.64M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $5.69M 10-KT · filed 2026-03-16 |
| 2025-09-30 | $5.74M 10-Q · filed 2025-11-06 |
| 2025-05-25 | $5.80M 10-K · filed 2025-08-07 |
| 2025-02-23 | $5.85M 10-Q · filed 2025-04-03 |
| 2024-05-26 | $3.21M 10-K · filed 2024-08-26 |
| 2023-05-28 | $3.21M 10-K · filed 2024-03-20 |
| 2022-05-29 | $12.00K 10-K/A · filed 2023-03-16 |
| 2021-05-30 | $3.31M 10-K · filed 2021-07-29 |
| 2020-05-31 | $3.44M 10-K · filed 2020-08-14 |
| 2020-02-23 | $3.47M 10-Q · filed 2020-04-03 |
| 2019-11-24 | $3.50M 10-Q · filed 2020-01-02 |
| 2019-08-25 | $3.54M 10-Q · filed 2019-10-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |